지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals
Immune Network
2021 .02
코로나바이러스감염증-19 치료제 현황
보건의료기술평가
2020 .01
Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID
Infection and Chemotherapy
2024 .03
COVID-19 Outbreak in Malaysia
Osong Public Health and Research Persptectives
2020 .01
Age-Related Morbidity and Mortality among Patients with COVID-19
Infection and Chemotherapy
2020 .01
코로나바이러스감염증-19(SARS-CoV-2 감염증)의 임상 양상과 치료
임상이비인후과
2020 .01
Acute Confusion as an Initial Presentation of SARS-CoV-2 Infection
Journal of Clinical Neurology
2021 .01
COVID-19
International Neurourology Journal
2020 .01
Clinical experience with COVID-19 patients
한국실험동물학회 학술발표대회 논문집
2022 .01
Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the Republic of Korea
Osong Public Health and Research Persptectives
2020 .01
Empirical Treatment and Prevention of COVID-19
Infection and Chemotherapy
2020 .01
안과진료에서 COVID-19의 감염 위험과 예방
대한의사협회지
2021 .01
신경계 질환에 대한 COVID-19 범유행의 영향: 신경재활을 위한 제언
한국신경근육재활학회지
2021 .01
코로나바이러스감염증-19(COVID-19) 진단을 위한 검사실 검사
보건의료기술평가
2020 .01
Identification of Coronavirus Isolated from a Patient in Korea with COVID-19
Osong Public Health and Research Persptectives
2020 .01
COVID-19: An overview of current scenario
셀메드
2020 .08
The experience of infection prevention for coronavirus disease 2019 (COVID-19) during general anesthesia in an epidemic of COVID-19: including unexpected exposure case - Two cases report -
Anesthesia and Pain Medicine
2020 .01
Severe acute respiratory syndrome coronavirus-2 대유행 중 알레르기 환자의 진료
Allergy Asthma & Respiratory Diseases
2021 .01
코로나19 판데믹 사태에서 대한진단검사의학회의 초기 대응 현황
Laboratory Medicine Online
2021 .10
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes
Gut and Liver
2023 .01
0